Treats amblyopia 1.1 Cycloplegia 1.2 Mydriasis 1.3 Penalization of the healthy eye in the…. ANDA 215618, held by Somerset Theraps LLC. Atropine Sulfate.
As of Nov 16, 2026, ANDA 215618 (Atropine Sulfate), held by Somerset Theraps LLC, was first approved by FDA on Jul 1, 2024, with 0 approved supplements and 0 published complete response letters.
Atropine sulfate ophthalmic solution, 1% is indicated for: Atropine is an anti-muscarinic agent indicated for: Cycloplegia Mydriasis Penalization of the healthy eye in the treatment of amblyopia 1.1 Cycloplegia 1.2 Mydriasis 1.3 Penalization of the healthy eye in the treatment of amblyopia
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 1, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atropine Sulfate1% · solution/drops;ophthalmic | Atropine Sulfate | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters